small molecule

ACETAMINOPHEN

Loss of exclusivity—loss of exclusivity

CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand name	ACETAMINOPHEN
Active ingredient	ACETAMINOPHEN
Strength	650MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	SUPPOSITORY
Route	RECTAL
Modality	Small molecule
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.